Literature DB >> 19779962

Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome.

Bharat Bhushan1, Pradeep Singh Chauhan, Sumita Saluja, Saurabh Verma, Ashwani Kumar Mishra, Saeed Siddiqui, Sujala Kapur.   

Abstract

Occurrence of aberrant phenotypes in childhood and adult acute leukemia (AL) differs considerably in independent studies and their association with prognostic factors is still controversial. In the present study, 214 patients with AL (106 children and 108 adults) were evaluated for the aberrant expression of CD33 in ALL (B cell and T cell) and CD3, CD5, CD7, and CD19 in AML. In B-ALL, aberrant expression of CD33 was found in 39 and 23% cases of adult and children, respectively. In T-ALL, CD33 was seen in 33% cases of adults while in children CD33 was not observed. In AML, aberrant expression of CD19 was expressed in 52 and 32% while CD7 was expressed in 14 and 15% cases of childhood and adult AML, respectively. Among FAB subtypes, aberrant expression of CD19 and CD7 was more commonly seen in M5 subtype. One adult patient (AML-M5) showed expression of CD3, CD5, and CD19. In summary, aberrant phenotype was commonly seen in adults than childhood B-ALL while in AML, aberrant phenotype was more common in children than adults. CD19 was most commonly expressed antigen followed by CD7 in both childhood and adult AML. Interestingly, aberrant phenotype was not found in childhood T-ALL; however, it was seen in 33% cases of adults. We did not find any association of aberrant phenotype with adverse prognosis factors, CD34 marker, and clinical outcome except the absence of auer rod which was found to be significantly associated with aberrant phenotype of childhood AML (P = 0.01).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19779962     DOI: 10.1007/s10238-009-0067-8

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  45 in total

1.  Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression.

Authors:  N Cascavilla; P Musto; G D'Arena; S Ladogana; R Matera; M Carotenuto
Journal:  Haematologica       Date:  1997 Jan-Feb       Impact factor: 9.941

2.  Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones.

Authors:  H Firat; R Favier; M Adam; G Leverger; J Landman-Parker; Y Cayre; L Douay
Journal:  Leuk Lymphoma       Date:  2001-06

3.  Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma.

Authors:  K Kita; H Miwa; K Nakase; K Kawakami; T Kobayashi; S Shirakawa; I Tanaka; C Ohta; H Tsutani; S Oguma
Journal:  Blood       Date:  1993-05-01       Impact factor: 22.113

4.  Aberrant expression of T-cell markers in acute myeloid leukemia.

Authors:  Robert E Lewis; Julius M Cruse; Catherine M Sanders; Rachel N Webb; Jeanann L Suggs
Journal:  Exp Mol Pathol       Date:  2007-09-07       Impact factor: 3.362

5.  A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China.

Authors:  Jine Zheng; Xingbing Wang; Yu Hu; Jing Yang; Jun Liu; Yanli He; Qing Gong; Junxia Yao; Xiaoqing Li; Wen Du; Shiang Huang
Journal:  Cytometry B Clin Cytom       Date:  2008-01       Impact factor: 3.058

6.  Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia.

Authors:  R E Sobol; R Mick; I Royston; F R Davey; R R Ellison; R Newman; J Cuttner; J D Griffin; H Collins; D A Nelson
Journal:  N Engl J Med       Date:  1987-04-30       Impact factor: 91.245

7.  Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis.

Authors:  H A Preti; Y O Huh; S M O'Brien; M Andreeff; S T Pierce; M Keating; H M Kantarjian
Journal:  Cancer       Date:  1995-11-01       Impact factor: 6.860

8.  Clinical significance of childhood acute myeloid leukemias expressing lymphoid-associated antigens.

Authors:  S Kawai; Z Zha; Y Yamamoto; H Shimizu; T Fujimoto
Journal:  Pediatr Hematol Oncol       Date:  1995 Sep-Oct       Impact factor: 1.969

9.  Characterization of aberrant phenotypes in acute myeloblastic leukemia.

Authors:  A Macedo; A Orfão; M B Vidriales; M C López-Berges; B Valverde; M González; M D Caballero; F Ramos; M Martínez; J Fernández-Calvo
Journal:  Ann Hematol       Date:  1995-04       Impact factor: 3.673

10.  Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood.

Authors:  S R Wiersma; J Ortega; E Sobel; K I Weinberg
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

View more
  11 in total

1.  Aberrant phenotype in Iranian patients with acute myeloid leukemia.

Authors:  Mehdi Jahedi; Karim Shamsasenjan; Zohreh Sanaat; Mohammadreza Aliparasti; Shohreh Almasi; Mozhdeh Mohamadian; Babak Nejati; Amir Kamalifar; Ali Akbar Movassaghpour
Journal:  Adv Pharm Bull       Date:  2013-12-23

2.  Immunophenotypic characteristics of T lineage acute lymphoblastic leukemia: absence of immaturity markers-TdT, CD34 and HLADR is not uncommon.

Authors:  Richa Gupta; Neha Garg; Mrinalini Kotru; Dilip Kumar; Rajesh Pathak
Journal:  Am J Blood Res       Date:  2022-02-15

3.  T-cell acute lymphoblastic leukemia with co-expression of CD56, CD34, CD117 and CD33: A case with poor prognosis.

Authors:  Rafet Eren; Ceyda Aslan; Osman Yokuş; Mehmet Hilmi Doğu; Elif Suyani
Journal:  Mol Clin Oncol       Date:  2016-06-13

4.  Flowcytometric immunophenotypic profile of acute leukemia: mansoura experience.

Authors:  Dalia A Salem; Sherin M Abd El-Aziz
Journal:  Indian J Hematol Blood Transfus       Date:  2011-09-21       Impact factor: 0.900

5.  High mTOR expression independently prognosticates poor clinical outcome to induction chemotherapy in acute lymphoblastic leukemia.

Authors:  Asheema Khanna; Bharat Bhushan; Pradeep Singh Chauhan; Sunita Saxena; Dipendra Kumar Gupta; Fouzia Siraj
Journal:  Clin Exp Med       Date:  2017-10-26       Impact factor: 3.984

Review 6.  Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia.

Authors:  Haneen Shalabi; Anne Angiolillo; Terry J Fry
Journal:  Front Pediatr       Date:  2015-10-01       Impact factor: 3.418

7.  T-cell Acute Lymphoblastic Leukemia with del (7) (q11.2q22) and Aberrant Expression of Myeloid Markers.

Authors:  Ahmad Ahmadzadeh; Sajedeh Saedi; Kaveh Jaseb; Ali Amin Asnafi; Arash Alghasi; Najmaldin Saki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2013

8.  Expression of aberrant antigens in hematological malignancies: A single center experience.

Authors:  Aneeta Shahni; Madiha Saud; Saima Siddiqui; Samina Naz Mukry
Journal:  Pak J Med Sci       Date:  2018 Mar-Apr       Impact factor: 1.088

9.  Correlation of expression of aberrant immunophenotypic markers in T-ALL with its morphology: A pilot study.

Authors:  Neha Garg; Mrinalini Kotru; Dilip Kumar; Rajesh Pathak; Meera Sikka
Journal:  J Lab Physicians       Date:  2018 Oct-Dec

10.  Spectrum and Immunophenotypic Profile of Acute Leukemia: A Tertiary Center Flow Cytometry Experience.

Authors:  Nishit Gupta; Ravikiran Pawar; Sambhunath Banerjee; Subhajit Brahma; Asish Rath; Sundar Shewale; Mayur Parihar; Manish Singh; S R Arun; Shekhar Krishnan; Arpita Bhatacharyya; Anirban Das; Jeevan Kumar; Saurabh Bhave; Vivek Radhakrishnan; Reena Nair; Mammen Chandy; Neeraj Arora; Deepak Mishra
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-03-01       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.